Chronic hepatitis B (CHB) poses a major global health burden, with China particularly affected. Effective antiviral therapy ...

Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon ...

Please provide your email address to receive an email when new articles are posted on . The cumulative probability of functional cure was 14.53% at a mean age of 25.75 years. The annual cure rate was ...

New research delves into a traditionally overlooked category of chronic hepatitis B (CHB) patients. While those who are HBeAg-negative with normal ALT levels have been considered low-risk and often ...

Available treatments for hepatitis B e antigen (HBeAg)–negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically ...

Much of the liver injury in HBV infection reflects host immune response rather than a direct cytopathic effect of the virus. During the course of chronic HBV infection, biochemical dysfunction may be ...

Finally, because the patient is a chronic carrier of HBV, the alpha-fetoprotein level should also be monitored every 6 months and an ultrasound examination of the liver performed annually to screen ...

More than half of patients who suffer from chronic hepatitis B have the e antigen (HBeAg)-negative form of the disease. Even after many years of antiviral treatment with nucleos(t)ide analogues (NUC), ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...